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CHAPTER 1: INTRODUCTION 
 
Innovation and development of new technologies have revolutionized cancer care by 
refining diagnosis, advancing treatment, and improving prognosis of many cancers 
previously associated with substantial morbidity and mortality.  For example, the 
introduction of radiation therapy in conjunction with breast conserving surgery replaced 
previous dogma that insisted on radical and oftentimes disfiguring surgery in women with 
early stage breast cancer. 1-3 As such, the evolution of cancer technology has had a 
substantial impact in improving patient outcomes, safety, and quality of life.   
 
As newer cancer technologies diffuse into clinical practice, it is important to rigorously 
evaluate both factors that drive adoption and the implications of such adoption in terms 
of clinical effectiveness, costs, and overall value.  Such evaluation is critical to help 
inform clinical decision making and to ensure that high-quality and value-oriented care is 
achieved.  Many factors can affect the adoption of new cancer technologies such as 
clinical evidence, hospital factors, patient and physician preferences, reimbursement 
incentives, as well as regional and health system characteristics. Given that newer 
cancer technologies are often more expensive and reimbursed more heavily than the 
standard of care, there have been questions about cost-conscious care and non-clinical 
factors driving adoption. After the initial adoption of newer cancer technologies, it is 
important to understand their implications in terms of costs, quality, and cost-effective 
care. These implications are often complicated by the fact that many newer cancer 
interventions often disseminate into clinical practice during times when there is scant 
comparative effectiveness data supporting their benefit. Using formal cost-effectiveness 
analysis offers one standardized way to evaluate existing trial tested cancer 
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technologies and allows for estimating the incremental value of various cancer 
treatments relative to treatment guidelines. In addition, cost-effectiveness analysis is 
also valuable in assessing how much better newer technologies would have to be, and 
in particular those technologies that have been adopted in the absence of trial based 
evidence. Thus, an investigative framework that first evaluates factors that promote 
adoption of new cancer treatments and then assesses the cost-effectiveness of such 
adoption provides one way to longitudinally evaluate new technologies during different 
stages of clinical implementation.    
 
When considering factors that drive adoption of newer technologies, non-clinical factors 
are particularly important to consider because the combination of higher reimbursements 
and limited clinical evidence raises questions about incentives driving their use. Hospital 
level factors such as ownership status is one example of a non-clinical factor that may 
drive adoption and use. Hospitals play an integral role in investing in new technological 
infrastructure and have real incentives to attract patients and secure financial viability. 
Thus, financial incentives related to hospital ownership status may be one factor that 
promotes the adoption of new cancer treatments. Financial incentives, in general, have 
been speculated as a contributing factor to increased adoption of highly reimbursed 
therapies in prostate and breast cancer care. 4,5 However, little is known about the role of 
hospital ownership status on the adoption of highly reimbursed cancer therapies.  
 
In addition to financial incentives, enthusiasm and marketing of newer treatments may 
also affect the perception of newer cancer care technologies among both patients and 
providers and impact use and practice patterns. For example, enthusiasm for novel 
therapies may lead to new technologies being perceived as better than the current 
standard of care despite a lack of evidence demonstrating increased benefit. In addition, 
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there may also be a notion that more care with newer technologies is better care and 
associated with improved outcomes.  However, given the limited clinical evidence during 
early phases of adoption, the perception of new cancer technologies may not always be 
grounded with data proving their benefit. Therefore, it is important to comprehensively 
evaluate new technologies and understand factors that drive adoption such that new 
therapies are implemented responsibly and appropriately in clinical practice.  
 
After initial adoption of these newer therapies, assessing the cost-effectiveness of these 
technologies offers one way to measure value and compare various newer treatments 
on a standardized scale.   On the one hand, while costs may be higher, new 
technologies have the potential to improve patient quality of life and outcomes. However, 
in some settings new technologies have increased costs while having marginal or 
sometimes questionable benefit on clinical outcomes.6 This may be particularly true in 
the early phase of adoption, when data on effectiveness is scant. Thus, assessing the 
cost-effectiveness of both the standard of care and of newer treatment options can help 
inform clinical decision making for both patients and providers and offer guidance 
towards value-oriented cancer care.  
 
Towards this end, radiation therapy is a germane cancer technology to study because 
many new modalities are disseminating into clinical practice when there is scant 
evidence supporting their benefit.  More specifically, radiation therapy in the treatment of 
older women with early stage breast cancer is a meaningful scenario to consider 
because use of radiation in this population confers no survival advantage, provides 
minimal benefit, and can be safely omitted according to current trial-based guidelines. 7-
10 Moreover, newer radiation modalities have been increasingly adopted in the treatment 
of older women despite guidelines and trial-based evidence.11,12 These patterns of care 
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with newer radiation modalities raise questions about appropriate care, overuse, and 
cost-effective care. Two examples of newer breast radiation therapy modalities include 
brachytherapy and intensity modulated radiation therapy (IMRT). Modern breast 
brachytherapy involves catheter-based implantation of devices in the breast surgical 
cavity with later after-loading of high dose rate radiation sources to deliver radiation 
internally.13  Breast brachytherapy condenses the treatment course from 5-6 weeks to 1 
week. IMRT, on the other hand, is a variant of EBRT but allows for improved dose 
homogeneity and avoidance of some critical structures.14,15 These newer therapies have 
the potential benefits of reducing treatment related acute side effects, reducing late 
toxicity, and decreasing toxicity to surrounding breast, heart, and lung.13,16-18 However, 
clinical trial data comparing these newer modalities to the standard of care with external 
beam radiation has yet to mature with some preliminary studies suggesting that the risks 
may outweight potential benefit.19,20 
 
Thus, determining factors that drive adoption and assessing the cost-effectiveness of 
newer and unproven radiation therapy modalities has important consequences in 
understanding and informing clinical decision making. Comparing newer modalities 
compared to the standard of care using cost-effectiveness analysis further enables a 
standardized method to assess potential value of newer radiation modalities and provide 
a quantitative framework that can speculate either how costly or effective newer 
modalities would have to be in order to be cost-effective.  Therefore, we set out to 
determine the effect of hospital ownership status on the use of brachytherapy in the 
treatment of older women with early stage breast cancer. In a second study, we 
developed a decision analytic model to determine the incremental cost-effectiveness of a 
trial tested radiation therapy modality using external beam compared to guideline based 
treatment with no radiation in older women with early stage breast cancer. Finally, we 
5 	  
determined the cost-effectiveness of newer radiation modalities (IMRT and 
brachytherapy) in this patient population and determined how much more effective they 
would have to be in order to be cost-effective.   
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CHAPTER 2: HOSPITAL OWNERSHIP STATUS AND USE OF BRACHYTHERAPY 
 
2.1: ABSTRACT 
 
BACKGROUND:  Because the benefits of adjuvant radiation therapy (RT) for breast 
cancer decrease with increasing age, the use of expensive and unproven RT modalities 
such as brachytherapy in the treatment of older women has been questioned. In 
particular, patients and policy makers may be concerned that for-profit hospitals might 
be more likely to use therapies with higher reimbursements.  Among both younger and 
older Medicare beneficiaries with breast cancer, we examined whether hospital 
ownership status is associated with use of adjuvant brachytherapy. 
METHODS:  We conducted a retrospective study of female Medicare beneficiaries aged 
66-94 years old receiving breast-conserving surgery for invasive breast cancer in 2008 
and 2009. We assessed the relationship between hospital ownership and receipt of 
brachytherapy, as well as overall RT (i.e. brachytherapy or whole breast irradiation 
(WBI)) using hierarchical generalized linear models.  
RESULTS: The sample consisted of 35,118 women, 8.0% of whom had undergone 
surgery at for-profit hospitals.  Among patients who received RT, those who underwent 
surgery at for-profit hospitals were significantly more likely to receive brachytherapy 
(20.2%) than patients treated at not-for-profit hospitals (15.2%; Odds Ratio (OR) for 
profit vs. not-for profit: 1.50, 95% CI: 1.23-1.84). Among women 66-79 years old, there 
was no relation between hospital profit status and overall RT use.  However, among 
women age 80-94 years old, receipt of surgery at a for-profit hospital was significantly 
associated with higher overall RT use (1.22; 1.03-1.45) and brachytherapy use (1.66; 
1.18-2.34), but not WBI use (1.14; 0.96-1.36) 
 
CONCLUSIONS:  Medicare beneficiaries undergoing breast-conserving surgery at for-
profit hospitals were more likely to receive brachytherapy, a newer, less proven, and 
more expensive technology. Among the oldest women, who are least likely to benefit 
from RT, care at a for-profit hospital was associated with higher overall RT use, which 
was explained by higher utilization of brachytherapy in this subgroup 
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2.2: INTRODUCTION 
The adoption of new unproven technologies and the associated increase in costs of 
cancer care has raised concerns about inappropriate care and overuse, especially in 
light of current value-oriented healthcare initiatives.21-24 Many factors may affect the 
adoption of newer medical technologies including patient and physician preferences, 
reimbursement incentives, clinical evidence, and regional health system factors.25-28 
Hospitals play a major role in the adoption of new technologies, due to their ability to 
invest in infrastructure, their central role in the treatment of many conditions, and their 
being the focus of payer efforts to enhance quality and control costs.  Hence, it is 
important to understand how hospital factors, such as ownership status, affect the 
adoption of new technologies. 
 
The effect of ownership status is particularly relevant in clinical scenarios where 
evidence regarding treatment benefit is less definitive, and clinical decision-making is 
more discretionary. In this setting, hospitals owned by for-profit entities, which must 
return value to investors, may be more likely to encourage the adoption of highly 
reimbursed interventions.  While both for-profit and not-for-profit hospitals have financial 
incentives to emphasize revenue-generating procedures, for-profit hospitals may be 
more responsive to these incentives given their fiduciary interests.29-31 For example, for-
profit hospital ownership has been associated with increased use of cardiac 
revascularization interventions independent of clinical outcome.31  Similarly, receipt of 
care at for-profit hemodialysis centers has been associated with increased erythropoietin 
drug dosing in excess of recommendations from clinical guidelines.32 However, these 
studies focused on the use of widely used treatment strategies that had already 
disseminated into clinical practice with evidence-based guidelines in place.  Little is 
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known about the effect of hospital ownership status on the adoption of new medical 
technologies that are reimbursed at higher rates than existing technologies.33  
 
Breast brachytherapy for women with early stage breast cancer is an excellent example 
of a newer therapy with scant comparative effectiveness data and higher 
reimbursements compared to the standard whole breast irradiation (WBI). Given current 
trial based guidelines that recommend that radiation therapy using WBI after breast 
conserving surgery can be omitted in older women given limited clinical benefit, the use 
of a newer and unproven radiation modality, brachytherapy, raises questions about 
appropriate care and factors driving its adoption.4,34,35  Although breast brachytherapy 
has diffused into clinical practice, some recent data suggest that harms may actually 
outweigh the benefits.13,19,20,36-39  Furthermore, brachytherapy is more highly reimbursed 
than the standard of care, and some authors have suggested that financial interests are 
driving the adoption of brachytherapy in clinical practice. 4,40-42 It remains unknown 
whether care at a for-profit hospital is associated with the receipt of brachytherapy.  
 
It is also important to consider how the adoption of brachytherapy might affect overall 
use of adjuvant radiation therapy (RT). That is, after disseminating into clinical practice 
in either profit setting, brachytherapy may substitute for the standard of care, WBI, 
without any increase in the overall use of RT.  Alternatively, enthusiasm for 
brachytherapy could expand the pool of women who are assessed to be suitable 
candidates for RT and instead complement the standard of care, thereby increasing 
overall RT use. In this context, financial incentives and increased reimbursement for 
brachytherapy may lead to a higher overall use of RT. This may be particularly true 
among older women, and especially those above age 80 years, for whom the benefit of 
RT diminishes and thus may be more subject to provider preferences and discretionary 
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judgment.7-9,43 It remains unknown whether care at a for-profit hospital is associated with 
brachytherapy use as a substitute for standard RT or associated with a higher likelihood 
of RT use overall.  
 
To further our understanding of the relation between hospital ownership status and 
cancer care, we used national Medicare data to assess the relation between for-profit 
hospital ownership and the adoption of brachytherapy among Medicare beneficiaries 
with breast cancer receiving breast-conserving surgery (BCS). We hypothesized that 
among women receiving adjuvant RT, those who had undergone BCS at a for-profit 
hospital would be more likely to receive brachytherapy.  We also assessed whether 
women undergoing BCS at for-profit hospitals would be more likely to receive RT overall.  
That is, we hypothesized that the use of brachytherapy in for-profit hospitals increases 
the proportion of women who are receiving RT, rather than simply substituting for WBI. 
We also hypothesized that this relation between brachytherapy and overall RT use 
would be stronger among older women, the group for whom RT is more discretionary.  
 
2.3: METHODS 
Data Source and Study Sample 
Using the Centers for Medicare and Medicaid Services Chronic Condition Warehouse 
(CCW) database, we identified a sample of female Medicare beneficiaries between ages 
66-94 years who received BCS and adjuvant RT for invasive breast cancer in 2008 and 
2009.44,45 The CCW is a national database that contains 100% of fee-for-service 
Medicare claims for inpatient and outpatient institutional and non-institutional services for 
patients with certain chronic conditions. We identified beneficiaries with invasive breast 
cancer by the International Classification of Diseases, 9th revision (ICD-9) diagnosis 
code (174.x). Receipt of brachytherapy or other forms of adjuvant RT (external beam, 
intensity modulated) was identified according to Healthcare Common Procedure Coding 
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System codes (HCPCS; Appendix 2.1). We only included women who received BCS 
between January 2008 and June 2009 and were enrolled in fee-for-service Medicare 
Parts A and B during the study period. Approximately 93% of all Medicare beneficiaries 
are enrolled in both Parts A and B.46  Women were excluded from this sample if they 
received an ICD-9 diagnosis code for any other cancer (including ductal carcinoma in 
situ) in the 9 months prior through 6 months after BCS (Appendix 2.2). This study used 
de-identified patient data and was classified by the Yale Human Investigation Committee 
as nonhuman subjects research and was exempted from a full review.  
 
Radiation Therapy 
Patients with any HCPCS codes indicative of brachytherapy treatment were considered 
to have received brachytherapy. Patients with at least four HCPCS codes indicative of 
the delivery of WBI with external beam RT (either standard or intensity modulated) were 
considered to have received WBI. In order to capture all patients for whom the decision 
was made to provide brachytherapy as a component of their therapy, patients with codes 
for both brachytherapy and WBI (less than 0.5% of the total sample) were assigned to 
the brachytherapy group.  
 
Construction of Variables 
Patient characteristics included age, race, year of surgery, residence in a metropolitan 
county based on Core Based Statistical Areas, and median household income at the zip 
code level. Clinical characteristics such as comorbid conditions, tumor laterality, lymph 
node evaluation, and receipt of chemotherapy were assessed using HCPCS and ICD-9 
codes from the Medicare claims (Appendix 2.1). As proxies for access to care, we 
accounted for each of the following variables in the year prior to surgery: any hospital 
admission, screening mammogram, receipt of a flu shot, or primary care physician visit. 
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Comorbid conditions previously found to be associated with survival in non-cancer 
patients were assessed by searching claims in the 12 months through one month prior to 
BCS.47 We included ICD-9 diagnosis codes that were on an inpatient claim or ≥2 
outpatient/physician claims billed >30 days apart.  
 
For each patient, we identified the hospital at which BCS was performed using the 
Medicare provider number. Hospital ownership was determined from the Medicare 
Hospital General Information dataset which is a self-reported measure by hospitals 
during enrollment with the Centers for Medicare and Medicaid Services.48 All hospitals 
listed as ‘Proprietary’ under the hospital owner variable were considered for-profit. 
Hospitals listed as either ‘Government’ or ‘Voluntary Non-profit’ were considered not-for-
profit. Patients for whom we could not identify a BCS-performing hospital or whose 
hospital was not included in the Hospital General Information dataset were excluded 
from analyses (n=6,194, 15%). Hospital volume was calculated as the number of 
patients in our sample who received surgery at each hospital during the study period. 
The sample was categorized into quintiles of volume such that each quintile had 
approximately the same number of patients. We assessed hospital volume to account 
for any confounding association between volume and use of RT. Conceivably, higher 
volume hospitals may prefer a shorter course radiation therapy modality such as 
brachytherapy regardless of profit-status to ensure a target operating volume. 
 
Patients were assigned to hospital referral regions (HRR) based on zip-code of 
residence using a cross-walk available from the Dartmouth Atlas of Healthcare.49 We 
assessed regional level factors that could be associated with the location of a for-profit 
hospital and use of brachytherapy including the presence of a state certificate of need 
(CON), two-year mammography rate, and radiation oncologist density for each HRR. 
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The CON variable was used to assess the presence of policies that regulated the 
opening of new radiation facilities during the study period. The presence of a state CON 
was determined using the National Conference of State Legislatures online resource and 
the American Health Planning Association National Directory annual report published 
during our study period.50,51 We hypothesized that the presence of a state certificate of 
need may affect RT use by for-profit hospitals because there may be greater barriers in 
these states to open new radiation facilities and expand the referral base for radiation 
delivery.  We hypothesized that both two-year mammography rate, an indicator for 
screening practices for a given HRR, and radiation oncologist density might be 
associated with the use of RT because these regional characteristics may increase both 
the incidence rate of invasive breast cancer and access to RT.  
 
Statistical Analysis 
We used chi-square tests to determine the unadjusted association between hospital 
ownership and each covariate. We used hierarchical generalized linear models (HGLMs) 
with a logit link function to assess the unadjusted and adjusted relationship between 
hospital ownership and receipt of brachytherapy among patients who received RT.52 
HGLMs allowed us to account for the non-independence of outcomes by clustering 
patients within hospitals, which were clustered within HRRs. In all HGLMs, hospital and 
HRR were specified as random effects, while all other covariates were specified as fixed 
effects. We estimated an analogous model using receipt of any RT as our outcome in 
the full sample. Because RT can be considered optional in many women ≥70 years of 
age, we hypothesized that the effect of hospital ownership on receipt of any RT might be 
moderated by patient age. For this reason, we repeated this model with the addition of 
interaction terms between hospital ownership and age category and re-estimated the 
model separately among age groups with and without significant interactions. Finally, in 
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order to determine whether any association between hospital ownership and receipt of 
any RT was driven primarily by the differential use of brachytherapy rather than WBI 
among older women, we estimated two additional models in which the outcomes were 
receipt of brachytherapy (versus no RT) and receipt of WBI (versus no RT). All data 
analyses were performed using SAS version 9.2 (SAS Institute Inc., Cary, NC); HGLMs 
were estimated using the GLIMMIX procedure.  
 
*CCW database queries and statistical analysis using SAS were performed by Ms. 
Pamela Soulos MPH. 
 
2.4: RESULTS 
Overview of Study Sample and Hospital Characteristics  
Our sample included 35,118 beneficiaries who received BCS. The mean age was 74.2 
(SD: 5.9) and less than 6% of our sample was above age 85. The majority of women 
were white (91.1%). About 72% of the sample received adjuvant RT, of whom 22,496 
(88.9%) had undergone BCS at a not-for-profit hospital and 2,816 (11.1%) at a for-profit 
hospital. Among women who received RT, there were significant differences between 
women receiving care at a for-profit compared to not-for-profit hospital with regards to 
race, residence in a metropolitan county, median household income, and receipt of a flu 
shot (Table 2.1). Patients from for-profit and not-for-profit hospitals were similar in all 
other patient characteristics.  
 
Patients received care at 2,255 not-for-profit hospitals and 429 for-profit hospitals. 
Patients who received BCS at for-profit hospitals were more likely to receive surgery at 
lower surgical volume hospitals and reside in states without a CON for a radiation facility 
(63% of for-profit hospitals vs. 53% of not-for-profit hospitals, p<0.001). In addition, 
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patients who received BCS at for-profit hospitals were more likely to reside in HRRs with 
a lower mammography rate and fewer radiation oncologists per capita. 
  
Hospital Ownership and Receipt of Brachytherapy 
Among beneficiaries receiving RT, 15.7% received brachytherapy. Women at for-profit 
hospitals who received RT were more likely to receive brachytherapy (20.2%) than 
women at not-for-profit hospitals (15.2%, adjusted OR: 1.50, 95% CI: 1.23-1.84, 
p<0.001, Table 2.2). Women who received BCS at higher surgical volume hospitals were 
also more likely to receive brachytherapy. In addition, patients who had left sided 
tumors, lymph node evaluation and screening mammograms were all more likely to have 
received brachytherapy (p<0.001). In contrast, patients receiving chemotherapy were 
less likely to receive brachytherapy.   
 
Hospital Ownership and Receipt of Overall Radiation  
There was no association between hospital ownership and the overall use of RT. That is, 
73.1% of women undergoing BCS at a for-profit hospital subsequently received adjuvant 
RT, compared to 72.0% of women at not-for-profit hospitals (Figure 2.1, OR: 1.08, 95% 
CI: 0.97-1.20, p=0.18). However, the relation between hospital ownership and RT use 
varied across age groups.  
Among the oldest women (aged 80-94 years), those undergoing BCS at a for-profit 
hospital were more likely to receive any RT compared to women receiving care at a not-
for-profit hospital (Figure 2.1, 58.9% vs. 53.9%, OR: 1.22, 95% CI: 1.03-1.45, p=0.03). 
There was no significant difference in receipt of RT according to hospital profit status 
among women age 66-79 (78.1% vs. 78.8%, p=0.74) 
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The increased use of RT among older women at for-profit hospitals was associated 
primarily with receipt of brachytherapy. Specifically, women aged 80 and over receiving 
BCS at a for-profit hospital were more likely to receive brachytherapy (12.4% at for-profit 
vs. 8.0% at not-for-profit, OR for brachytherapy compared to no RT: 1.66, 95% CI: 1.18-
2.34, p=0.003) while there was no relation between ownership status and the receipt of 
WBI (46.5% at for-profit vs. 45.9% at not-for-profit, OR for WBI vs. no RT: 1.14, 95% CI: 
0.96-1.36, p=0.13).  
 
2.5: DISCUSSION 
We found that Medicare beneficiaries who underwent BCS at for-profit hospitals 
disproportionately received the more expensive and less proven brachytherapy over the 
less expensive standard of care (WBI). Furthermore, older women (≥80) at for-profit 
hospitals received more RT overall, with this difference largely driven by the use of 
brachytherapy.  Thus, older women received more aggressive care at for-profit hospitals, 
despite being less likely to benefit from RT.9 
  
Several factors may have contributed to the increased use of brachytherapy for women 
receiving care at for-profit hospitals. Financial incentives may be one driving factor.12,40,53 
Prior studies have highlighted the high reimbursement for brachytherapy, suggesting 
that it is more revenue generating	  than the standard of care. 4,42,54 While high 
reimbursements do not necessarily equate to high profit margins, there has been 
concern that higher reimbursements have fueled adoption of brachytherapy.4,55-57 In 
response to these concerns, the Centers for Medicare and Medicaid Services reduced 
reimbursement for brachytherapy in 2008 and 2010. While we do not have actual profit 
margin estimates for brachytherapy in individual hospitals, our findings support previous 
reports suggesting that higher reimbursements may be contributing to the rapid adoption 
of brachytherapy.55-57 In other cancer care settings, it has also been suggested that 
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financial incentives drive the use of newer RT modalities such as intensity modulated RT 
in men with prostate cancer.5 Reduced reimbursement of chemotherapy has been 
associated with significant changes in patterns of chemotherapy use by oncologists.58-60 
In addition to direct financial incentives, leaders at for-profit hospitals may prefer 
adopting novel therapies as a way to build market share.  Indeed, hospital advertising 
has been shown to promote more advanced technology as a means to attract 
patients.61,62  
 
It is important to note that a driving factor in the adoption of brachytherapy is the attempt 
to enhance convenience and tolerability of treatment. Brachytherapy has the potential of 
delivering RT to patients who otherwise may not seek treatment due to concerns about 
treatment length and toxicity, and may be a reason for some older women to choose 
brachytherapy over standard RT. However, it is unclear why patient preferences for 
radiation modality would vary with hospital ownership.  Given that women older than 80 
years of age are least likely to benefit from radiation overall in terms of improvements in 
cancer control, our analysis suggests that brachytherapy may be increasing accessibility 
to RT overall, but not necessarily for women who benefit from it the most. 9,10  
 
Our study has important limitations.  First, we defined hospital ownership as either not-
for-profit or for-profit which does not distinguish hospital behavior that can exist in both 
profit settings.63 We grouped hospitals listed as ‘Government’ or ‘Voluntary Non-profit’ as 
not-for-profit because of our hypothesis that for-profit hospitals in particular might adopt 
brachytherapy to a greater extent compared to other hospital types.63 However, hospital 
behavior can align with financial incentives within not-for-profit organizations as well.63,64 
Therefore, coarse classification of ownership into either for-profit or not-for-profit may 
obscure financial factors that affect brachytherapy use. Second, we examined only 
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Medicare beneficiaries, who may not be representative of the patterns of brachytherapy 
utilization in younger patient populations or in patients with private insurance or no 
insurance. Third, we did not consider the decreases in the Centers for Medicare and 
Medicaid Services reimbursement for breast brachytherapy, the first of which took effect 
in January 2009.4 However, our study illustrates the pattern of brachytherapy use when 
reimbursement was higher. While our results suggest that the year when treatment 
occurred did not affect receipt of brachytherapy, future work exploring how these 
changes affect brachytherapy utilization will add to our understanding of financial 
incentives and adoption of new technologies of cancer care. Fourth, our analysis does 
not account for provider factors such as physician reimbursement structures that may 
differ between hospitals. Our analysis does not examine the effect of ownership status of 
free-standing RT facilities which also provide RT for patients and may respond differently 
to financial incentives. Instead, we chose to use hospital ownership where BCS was 
performed because patients who are referred for RT eventually seek treatment at either 
hospital-based facilities, freestanding facilities, or seek no RT treatment. Thus, 
determining the effect of hospital ownership rather than RT facility ownership captures 
an earlier point in the clinical decision making process. Finally, it is important to 
acknowledge that the long-term risks and benefits of brachytherapy are still being 
defined; the current work is focused on the adoption of brachytherapy during a time 
when there was scant comparative evidence concerning either benefits or risks. Future 
work should explore patterns of brachytherapy use in non-hospital based settings and 
how patterns of care respond to data forthcoming from ongoing clinical trials.  
 
Our study extends the current literature by examining how hospital ownership affects the 
adoption of newer, more expensive cancer technologies and suggests that for-profit 
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hospitals may be emphasizing revenue-generating RT interventions, leading to more 
aggressive care in patients who are likely to benefit less from treatment. 	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CHAPTER 3: COST-EFFECTIVENESS OF RADIATION THERAPY MODALITIES 
 
3.1: ABSTRACT 
 
PURPOSE 
The use and limited benefit of radiation therapy in the clinical care of older women 
with favorable risk breast cancer have raised concerns about overuse, 
expenditure, and cost-effectiveness. Moreover, newer radiation therapy modalities 
such as intensity modulated radiation therapy (IMRT) and brachytherapy are 
diffusing into the clinical practice despite their increased costs and uncertain 
clinical benefit. We used Medicare data to:  (1) estimate incremental cost-
effectiveness ratios (ICERs) of external beam radiation therapy (EBRT) compared 
to no radiation; (2) incorporate age and comorbidity into cost-effectiveness 
estimates of EBRT; (3) evaluate the cost-effectiveness of newer radiation 
modalities. 
 
METHODS 
Using the Surveillance, Epidemiology, and End Results-Medicare database, we 
identified women who fulfilled the Cancer and Leukemia Group B C9343 trial 
criteria (>70 years of age, tumor size ≤2cm, estrogen-receptor positive status, 
node negative) and in whom the use of radiation can be safely omitted. We 
estimated the annual recurrence, annual metastasis and determined 10-year 
survival rates according to receipt of EBRT. We determined cancer-related costs 
to Medicare from a payer perspective. Assuming that all radiation modalities have 
equivalent effectiveness, we used a Markov decision model to calculate ICERs for 
each modality compared to no radiation therapy over a 10-year time horizon. We 
determined the ICERs for various radiation modalities by age and comorbidity 
status. 
 
RESULTS 
The median incremental radiation-related cost associated with EBRT compared to 
no radiation was $10,308. The cost-effectiveness ratio of EBRT compared to no 
radiation for the full study sample was $43,015/QALY, and increased with 
increasing age, ranging from $36,675 (ages 70-74) to $51,375 (ages 80-94) per 
QALY.  The ICER for EBRT among the oldest women with the most comorbidities 
reached $343,333/QALY.  The number needed to treat with radiation to prevent 
one recurrence was 125. The median incremental cost was $19,254 for IMRT and 
$18,249 for brachytherapy. Newer treatments would have to be at least 30% more 
effective to be cost-effective. 
 
 
CONCLUSIONS 
EBRT is cost-effective for a many older women with early stage breast cancer, but 
substantially less cost-effective for older women with multiple comorbidities. 
Newer radiation modalities would have to be less costly or substantially more 
effective in improving quality of life to be cost-effective.  
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3.2: INTRODUCTION 
While the use of external beam radiation therapy (EBRT) after breast-conserving surgery 
(BCS) has been proven in clinical trials to improve local control and survival in women 
with early stage breast cancer, this effect has not been shown in an elderly population 
that typically has more indolent disease. 2,7,8,13,16,65-67 In fact, current trial-based 
recommendations suggest that adjuvant radiation therapy may be omitted in women >70 
years of age with certain low-risk tumor characteristics. 34,35 Despite these guidelines, 
radiation therapy continues to be used in older women, raising concern about overuse. 11 
The hesitation to change practice patterns in light of clinical evidence may be due to 
both the reduction in local recurrence associated with radiation therapy and the 
challenges inherent in incorporating the multifactorial effects of age and comorbidity into 
decision-making.   
 
In our resource-strained healthcare system, we must consider the substantial costs and 
cost-effectiveness of radiation therapy in this population.12,40 Formal cost-effectiveness 
analyses, integrating effectiveness data from well-designed clinical trials with cost data 
from clinical practice, are widely used tools for informing decision-making.  Yet in some 
instances, new technologies diffuse into clinical practice in the absence of comparative 
effectiveness data.  In this context, a framework is needed to allow practitioners and 
policy makers to assess newer cancer treatments in the absence of substantial clinical 
data. To address this need, cost-effectiveness analysis can be used in a different way by 
first traditionally assessing existing trial-tested interventions. Cost-effectiveness analysis 
can then be used to project how much more effective newer interventions would have to 
be in order to be cost-effective.  
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Radiation therapy in the treatment of older women with breast cancer is a salient 
example of a cancer technology that is continuously evolving and disseminating into 
clinical practice despite limited comparative effectiveness data. 55,68 Newer and high cost 
modalities such as brachytherapy and intensity modulated radiation therapy (IMRT) are 
being adopted while clinical trials comparing them to the standard of care (EBRT) are 
still ongoing. 4,12,16,41,55,69  These newer therapies have the potential benefits of reducing 
treatment-related side effects but are substantially more costly. 13,16-18,53 Notably, 
brachytherapy has not demonstrated any benefit on cancer control or overall or disease 
free survival compared to EBRT and may be inferior to EBRT in subsequent mastectomy 
rate and risk of complications. 19,20 IMRT has demonstrated a reduction in late toxicity 
and improvement in clinical measures of breast appearance, but it is unclear how IMRT 
affects patient reported quality of life. 14,70 Therefore, it is important to understand the 
balance between the costs of IMRT and brachytherapy and the potential benefits of 
reduced toxicity and improved cosmesis.  
 
We therefore set out to estimate incremental cancer-related costs and cost-effectiveness 
for EBRT, using actual Medicare expenditures to estimate total cancer-related costs. 
Secondly, since life expectancy has a strong relation to the time at risk for breast cancer 
recurrence, and therefore of the effectiveness of radiation therapy, we used actual 
survival data of older women to estimate 10-year survival across life expectancy groups, 
defined by age and comorbidity burden. Finally, we explored the incremental costs for 
the newer radiation therapy modalities and projected how much more effective they 
would have to be relative to EBRT to be cost-effective.	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3.3: METHODS 
Basic Model 
We designed a Markov decision model to simulate clinical outcomes, estimate quality-
adjusted life-years (QALYs) gained, and determine the incremental cost-effectiveness 
ratio (ICER) of radiation therapy from a payer perspective over a 10-year horizon in older 
women (≥70 years of age) with early stage breast cancer. Our base case scenario was 
based on current treatment guidelines. That is, our base case scenario was of older 
women with early stage breast cancer who had undergone breast-conserving surgery 
but had received no radiation therapy. We used this model to compare the costs and 
health benefits of various radiation modalities (EBRT, IMRT, brachytherapy) compared 
to no radiation therapy. We estimated the cost-effectiveness of the newer modalities 
(IMRT and brachytherapy) compared to no radiation under the assumption that they had 
equal effectiveness to EBRT in terms of overall and recurrence-free survival and utility. 
We then estimated the improvement in effectiveness for the newer modalities that would 
be necessary in order for them to be below two commonly cited willingness to pay 
thresholds of $50,000/QALY and $100,000/QALY. Three hypothetical cohorts of women 
starting at ages 70, 75, and 80 were created to determine the effect of age. We assumed 
that all women enter the simulation in a no recurrence health state and subsequently 
transition to one of four health states (no recurrence, recurrence, metastasis, or death) 
each year (Appendix 3.1). We assumed the recurrence-related decrements in utility 
lasted for 2 years, during which a woman could transition to metastatic and death states 
or remain in the no recurrence state.71  Alternate windows were explored in sensitivity 
analysis. We chose to use a 10-year time horizon to be conservative in our assumptions 
regarding the long-term benefit of radiation therapy in older women. Since current 
treatment guidelines are based on the results from the C9343 trial, which has accrued 
data for 10.5 years, we chose to constrain our model to a time-period during which 
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radiation use has been proven to have no survival benefit.  All analyses were performed 
on TreeAge Pro 2012 (Williamstown, MA) and SAS version 9.2 (SAS Institute Inc., Cary, 
NC).  
 
Data Source and Model Assumptions 
We determined cost inputs and transition probabilities for recurrence, metastatic, and 
death states by using the National Cancer Institute’s Surveillance, Epidemiology, and 
End Results (SEER)-Medicare database. Using this database, we identified a sample of 
women who met eligibility criteria for the C9343 trial (≥70 years of age, tumor size ≤2cm, 
estrogen-receptor positive status, lymph node negative), were diagnosed in 1998-2007, 
and received BCS. The SEER-Medicare database is assembled from population-based 
cancer registries and links cancer incidence and survival information with Medicare 
claims 72. We selected women who fulfilled C9343 criteria because the results from this 
randomized controlled trial shaped current recommendations that state radiation therapy 
can be safely omitted in these older women and thus our model parameters will reflect 
characteristics of a population for whom there are distinct trial based guidelines. We 
estimated 10-year survival according to age group in women who were diagnosed in 
1998-1999, for whom we had 10 years of follow-up data and determined an annual 
mortality rate.  We estimated recurrence and metastasis rates in our sample by using a 
previously validated administrative algorithm.73 In brief, we used the high specificity, high 
positive predictive value algorithm to identify recurrences and metastatic events in our 
sample. Consistent with prior work, recurrences were estimated by determining the rate 
of secondary mastectomy, which has been shown to mirror randomized clinical trial data 
on effectiveness closely. 9,73 Of note, we assigned any patient with metastasis diagnosis 
codes and a subsequent non-breast cancer diagnosis in SEER to the “no metastasis” 
group. We used published SEER data to determine breast cancer specific mortality from 
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metastatic disease and calibrated our model to obtain overall survival estimates that 
were consistent with our sample survival data. 74 Our input parameters were based on a 
sample of all women who fulfilled C9343 criteria but did not necessarily receive radiation 
therapy to account for any selection bias in choosing women who had either received 
radiation or no radiation therapy. All mortality, recurrence, and metastasis rates were 
converted to annual transition probabilities as model inputs (Table 3.1).  
 
Radiation Therapy 
Patients were considered to have received radiation therapy if their Healthcare Common 
Procedure Coding System codes indicated that they received at least four treatments of 
EBRT or IMRT or at least one treatment of brachytherapy (Appendix 3.2).  Patients with 
codes for both brachytherapy and other modalities were assigned to the brachytherapy 
group because they were exposed to the incremental cost as well as potential for toxicity 
associated with brachytherapy.  
 
Cost Inputs 
Each cancer patient was matched to a non-cancer control based on age, race, 
comorbidity, region, and year of diagnosis (or year of randomly assigned index date for 
control patients). Total median costs were calculated as all costs to Medicare (including 
inpatient, outpatient facility, physician, home health, hospice, and DME claims) from a 
payer perspective in the 2 months before through 12 months after date of 
diagnosis/index date. We used median costs instead of mean costs to be more 
conservative in our cost estimates and prevent outliers from skewing the analysis. Each 
cancer patient’s cancer-related cost was calculated as the difference between her total 
cost and that of her matched control (Table 3.1). The costs were adjusted to 2009 US 
Dollars using the Prospective Payment System and Geographic Adjustment Factor for 
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inpatient services and the Medicare Economic Index and Geographic Practice Cost 
Index for outpatient services. 75,76 Cost of metastatic breast cancer care in Medicare 
beneficiaries was determined from the literature. 77 We estimated the continuing cost of 
care in the second through ninth year after diagnosis using the same approach. Within 
each year we restricted the sample used to calculate continuing cost to patients who 
fulfilled the following criteria through the end of the following year: continuously enrolled 
in fee-for-service Medicare and free from mastectomy, metastasis, and death.  Costs in 
the year before death were also calculated for all cancer patients who were continuously 
enrolled in fee-for-service Medicare from diagnosis until death (Table 3.1). 
 
Utility Inputs 
We abstracted utility weights for each health state from the literature and then age-
adjusted these utilities for older women at 5-year increments using previously reported 
trends 63,71,78. For example, women who entered a simulation at age 70 would 
experience an initial set of utilities for various health states and these utility weights 
would decrease once a surviving member of the cohort turned 75 or 80. Utilities varied 
based on age, receipt of radiation therapy, and metastatic and recurrence status and 
were discounted at an annual rate of 3% (Table 3.1).  
 
Life-Expectancy and Comorbidity Analysis 
To assess the effect of varying survival and comorbidity burden, we constructed a 
separate non-cancer sample by randomly selecting a subset of 50,000 women aged 67-
94 each year between 1998 and 1999 to allow for 10-year follow-up. We chose to use 
survival data from a non-cancer sample to determine age and comorbidity stratified cost-
effectiveness estimates to allow for adequate sample size for each combination. Using 
our non-cancer sample, we determined age and comorbidity combinations that 
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corresponded to different 10-year survival quartiles (0-25%, 25-50%, 50-75%, 75-100%).  
Combining these data, we estimated ICERs for EBRT by age and comorbidity. 
 
Sensitivity Analysis 
We performed a 1-way sensitivity analysis to assess the robustness of our model by 
determining the variability in incremental cost-effectiveness as a function of cost of 
radiation therapy, utility of radiation therapy, recurrence rate, metastasis rate, discount 
rate, cost of recurrence, and time-span of utility decrement upon entering a recurrence 
state. Recurrence and metastasis rates were varied between our estimates and trial-
based data. Cost of radiation therapy was increased and decreased by 50%, the upper 
limit corresponding to the cost of the newer modalities. The incremental utility benefit of 
radiation therapy in both the recurrence and no recurrence state was varied by ±50%. 
We varied the number of years of decreased utility after experiencing a recurrence 
between one and five years. Using a threshold of $100,000/QALY, we determined how 
much more effective newer radiation modalities would have to be in terms of QALYs in 
order to be cost-effective. 
 
*SEER-Medicare database queries were performed by Ms. Pamela Soulos MPH. 
 
 
3.4: RESULTS 
We included 18,340 Medicare beneficiaries who met the C9343 eligibility criteria. The 
10-year survival among all women varied between 73.6% for women aged 70-74 and 
33.4% for women aged 80-94 (Table 3.1). We estimated the annual mastectomy 
probability to be 0.36% in patients receiving no radiation and 0.27% in patients receiving 
radiation.  
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We estimated the total costs for a 70-year old woman receiving EBRT during 10-years 
follow-up to be $41,703 compared to $31,434 for no radiation, resulting in an 
incremental cost of $10,269 (Table 3.2). Similarly, we estimated the QALYs experienced 
for a 70-year old woman to be 7.30 for EBRT and 7.02 for no radiation resulting in an 
ICER for EBRT of $36,675/QALY. ICERs for EBRT increased with increasing age, with 
an 80-year old woman experiencing 5.18 QALYs with EBRT and 4.98 with no radiation, 
corresponding to a cost-effectiveness ratio of $51,375/QALY. Using an age-weighted 
average, we calculated cost-effectiveness of EBRT for all women in our sample to be 
$43,015/QALY. The cost-effectiveness for EBRT varied by age and comorbidity status 
(Figure 3.1).  Older women with more comorbidity had a decreased 10-year survival 
probability which corresponded to substantially less favorable cost-effectiveness for 
EBRT. Specifically, the ICER for EBRT was between $33,116/QALY and $44,652/QALY 
for women with predicted 10-year survival between 100% and 75% (corresponding to 
women aged 70-74 with no comorbidity). The ICER for EBRT increased between 
$57,122/QALY and $343,333/QALY women with predicted survival between 25% and 
0%.  
 
The median cancer-related costs per patient receiving newer radiation therapy 
modalities were $25,240 for IMRT and $24,235 for brachytherapy. Compared to no 
radiation, the incremental radiation-related costs were $19,254 per patient for IMRT and 
$18,249 per patient for brachytherapy (Table 3.1). Compared to EBRT, the incremental 
radiation-related costs were $8,946 per patient for IMRT and $7,941 per patient for 
brachytherapy. Assuming the newer modalities were equally effective to EBRT, the cost-
effectiveness for a 70-year old woman was $68,625/QALY for IMRT and $65,036/QALY 
for brachytherapy when compared with no radiation (Table 3.2). The newer modalities 
were less cost-effective in 80-year old women and were estimated to be $96,105/QALY 
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for IMRT and $91,080/QALY for brachytherapy. In our full sample, the cost-effectiveness 
of IMRT and brachytherapy was $80,478/QALY and $76,230/QALY, respectively. The 
cost-effectiveness of the newer modalities also increased with decreasing 10-year 
survival probability (Figure 3.1). Specifically, the cost-effectiveness estimates for the 
newer modalities were between $58,732/QALY and $79,178/QALY for women with a 
predicted survival between 100% and 75%. In women with a predicted survival between 
25% and 0%, the cost-effectiveness estimates increased to be between $101,239/QALY 
and $608,033/QALY. 
 
Using one-way sensitivity analyses our cost-effectiveness estimates were sensitive to 
the cost of radiation therapy. The incremental cost-effectiveness ratio increased by 80% 
to $65,771/QALY when the cost of EBRT was increased by 50% and approached the 
cost of the newer modalities.  Our estimates were also sensitive to the utility of radiation 
therapy in women who had no recurrence. That is, when the incremental utility of 
radiation therapy was increased by 50% in women with no recurrence, the ICER for 
EBRT increased by 87% to $68,460/QALY. If we assigned zero utility benefit to radiation  
therapy compared to no radiation, then the base-case scenario of no radiation 
dominates our analysis. The ICER for EBRT was also sensitive to the number of years 
of decreased utility after experiencing a recurrence increasing to $50,831/QALY when 
we assumed the decreased utility would last for 5 years (Figure 3.2). Variations in the 
other variables changed our estimates by less than 5% (Figure 3.2). We found that IMRT 
and brachytherapy would have to improve QALYs by at least 28% or 56% in order to be 
cost-effective with a willingness to pay threshold of $100,000/QALY or $50,000/QALY, 
respectively (Figure 3.3).  
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3.5: DISCUSSION 
We found that EBRT is a cost-effective therapy for older women with early stage breast 
cancer as the ICER of $43,015/QALY for EBRT falls below the willingness to pay 
benchmark of $50,000/QALY that is typically considered acceptable 79,80. However, we 
found substantial variability in the cost-effectiveness of EBRT when considering variation 
in age and comorbidity. While there were many instances in which EBRT was cost-
effective in older women, the cost-effectiveness ratios surpassed both $50,000/QALY 
and a more conservative cited benchmark of $100,000/QALY with increasing age and 
comorbidity. Thus, our cost-effectiveness analysis provides one way to clarify concerns 
regarding the unclear effects between life expectancy and breast cancer treatment 
choices. 43 
 
Our results raise important questions about the cost-effectiveness of IMRT and 
brachytherapy.  Noting the absence of effectiveness data, our model facilitated cost-
effectiveness estimates at various levels of clinical effectiveness.  Notably, we found that 
if these newer modalities had similar effectiveness to EBRT, then their ICERs are above 
the benchmark of $50,000/QALY for women over 70 years with low-risk tumor 
characteristics. Moreover, at their current costs these newer modalities would have to be 
at least 30% more effective to be cost-effective. This study demonstrates a unique 
approach to evaluating newer cancer treatments as they are diffusing into clinical 
practice with limited effectiveness data. By using Medicare data to estimate both total 
cancer-related costs and clinical effectiveness parameters, this approach can be more 
broadly applied to other novel cancer treatments to inform patients, practitioners, and 
policy makers on cost-effective care and effectiveness goals of ongoing clinical trials.  
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Our study builds upon prior work by using the SEER-Medicare database to specifically 
consider total cancer-related costs and clinical effectiveness of radiation therapy in a 
population of older women in whom the necessity of radiation is more controversial. 81-83 
In contrast, prior studies evaluating the cost-effectiveness of radiation therapy focused 
on younger women (aged 55-60) in whom the benefit and necessity of radiation therapy 
is more definitive and derived cost and effectiveness parameters mostly from the 
literature.81-85 Our findings are consistent with prior work in that we also found EBRT to 
be cost-effective in women with early stage breast cancer with an ICER of less than 
$50,000/QALY. While prior work evaluating younger women estimated the ICER of 
radiation therapy to be $28,000/QALY, our results suggest that EBRT is less cost-
effective in older women, which is not surprising given differences in survival. While our 
study estimated recurrence probability to be lower than previous trials, our sensitivity 
analysis suggests that these differences were minor drivers of cost-effectiveness.  
 
There are important limitations to consider. First, our assumptions regarding utilities, 
while commonly cited in the literature, do not take into consideration different recurrence 
risks with current therapies, differential complication profiles of the newer therapies, and 
how patient preferences and functional status change among different age groups, 
factors that can all affect utility weights. 86,87 Instead, we assumed that the utilities for 
each mode of radiation were equivalent which may not be accurate.  The health utilities 
we used were from a study in which patients reported a quality of life benefit to radiation 
therapy compared to no radiation, presumably from the peace of mind that radiation 
therapy allowed.  Though this indicates that the long-term impact of standard breast 
radiation on overall quality of life is likely low, whether it actually improves quality of life 
for a patient for whom the benefit from radiation may be low is unclear. Despite the low 
risk of recurrence for most older women, there is a patient-specific risk tolerance which 
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must be considered.  Patients who are very risk averse are unlikely to accept a higher 
rate of recurrence by omitting radiation, and for these women, radiation may indeed 
have a long term quality of life benefit. While we can speculate how these parameters 
would affect our estimates, our projections would be strengthened with more information 
on how the utility function is affected by these parameters and with long-term data 
regarding the efficacy of these newer modalities.  
 
Furthermore, studying cost-effectiveness using a cohort of long surviving patients may 
place less emphasis on short-term complications.  Therefore, if patients place great 
importance on avoiding short-term toxicity or upon shorter radiation schedules (such as 
with brachytherapy), they may feel that more expensive treatment is justified, despite a 
lack of a large benefit as measured by improvement in the QALY forecast.  For example, 
if brachytherapy is associated with less severe acute skin reactions compared to EBRT, 
this may lead to a transiently increased utility for brachytherapy.  Despite this increased 
utility, however, the effect on the QALY forecast is likely minimal due to the relatively 
transient nature of skin reactions. In contrast, if brachytherapy significantly improves 
long-term breast outcomes such as cosmesis or late effects on the lung and heart, the 
effect on QALYs could be more significant. Other factors that may affect long-term utility 
and cost of these newer modalities include subsequent related procedures, screening 
and late toxicity.  For example, several studies have reported that patients receiving 
brachytherapy receive more surgery post therapy while others have pointed out that a 
subset of patients have persistent seromas that may require ultrasound or even excision. 
88-90 For IMRT, ongoing randomized controlled trials have reported a reduction in acute 
and long-term toxicity. 14 Therefore, if these factors change the utility or long-term costs 
of the newer modalities, then the target effectiveness will have to change 
correspondingly in order for these modalities to be cost-effective.  
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We also assumed that the recurrence risk is equivalent across all modalities. This is a 
tenuous assumption because brachytherapy may be less capable of treating occult 
multifocal disease compared to EBRT and is more prone to marginal miss (missing 
occult microscopic extension just beyond the excision cavity), which would ultimately 
lead to a larger difference in cost-effectiveness relative to EBRT. 91 Evidence from 
ongoing trials, thus, will be important to accurately build upon this model and to evaluate 
newer RT modalities.  
 
In summary, EBRT is cost-effective for most older women with early stage breast 
cancer. However, newer modalities such as IMRT and brachytherapy are costlier than 
EBRT and would have to be substantially more effective in improving cancer control or 
quality of life to achieve equivalent cost-effectiveness. As newer technologies 
disseminate into clinical practice, it will be important to provide data on comparative 
effectiveness relative to costs to better inform clinical decision-making. 
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CHAPTER 4: CONCLUSIONS & FUTURE DIRECTIONS 	  
4.1: SUMMARY 
We assessed the effect of hospital ownership status on the adoption of brachytherapy 
and estimated cost-effectiveness of new radiation technologies in the treatment of older 
women with breast cancer. We found that hospital for-profit status was related to the 
receipt of not only brachytherapy but also was related to higher overall radiation therapy 
use leading to potentially overly aggressive care in this population. We also found that 
while the current standard of care, EBRT, is relatively cost-effective for older women, 
newer modalities would have substantially improve quality of life or be more effective in 
order to be cost-effective. We also found that cost-effectiveness of radiation therapy 
modalities vary substantially with increasing age and comorbidity. Overall, the increased 
adoption of these newer therapies in older women raises important questions about not 
only cost-effective care but also about provider preferences and financial incentives that 
may promote use despite limited data on effectiveness.   
 
4.2: FUTURE DIRECTIONS 
For-Profit Ownership and Receipt of Brachytherapy 
While several factors may be related to the association between for-profit hospital 
ownership and receipt of brachytherapy, financial incentives may be one factor that can 
be tested further . Policy changes have led to decreased reimbursement and changes in 
coding structure for brachytherapy in breast cancer care. 4 Specifically, in 2008 Medicare 
reimbursement for each treatment delivered decreased. Also, the reimbursement 
structure changed to compensate number of catheters used instead of the number of 
dwell positions.  In 2010, surgeon reimbursement for brachytherapy device placement 
was also decreased. These two events enable an interesting experiment to assess the 
role of financial incentives. That is, if financial incentives were driving increased use of 
brachytherapy in older women then decreases in reimbursement may lead to decreased 
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use. On the other hand, if financial incentives are at play, then decreases in 
reimbursement may lead to changes in practice patterns in order to protect 
remuneration. For example, in order to protect compensation to levels commensurate 
with earlier reimbursement levels, practice patterns may shift towards more numerous 
catheter placement. However, if financial incentives are not driving increased 
brachytherapy use, then these effects may not be observed. Finally, determining the 
association between for-profit ownership status of free-standing radiation facilities and 
brachytherapy use may be another meaninful experiment to test the effect of financial 
incentives because free-standing radiation facilities may be more directly responsive to 
financial incentives than hospitals.  
 
Cost-Effectiveness of Newer Radiation Therapy Modalities 
 
We found that our cost-effectiveness estimates were particularly sensitive to utilities 
assigned to the various health states in our model. However, there is limited data 
characterizing utilities in women with early stage breast cancer receiving radiation 
therapy. We used utilities derived from the literature which may be dated and may not as 
accurately reflect the current perception of radiation therapy. The utilities used in our 
work also reflect a net benefit of radiation therapy over no radiation which is debatable in 
an older population given current evidence. Also, there have been no studies to our 
knowledge that have determined the utility of radiation therapy in older women 
specifically or the utility of the newer modalities. Thus, it will be important to direct future 
work towards understanding how older women percieve both the standard of care as 
well as the newer radiation modalities in terms of quality of life. In addition to the effects 
of age and technology, utility may change based on period in diagnosis, treatment, and 
post-treatment which will affect cost-effectiveness estimates. Finally, up to date utilities 
may be particularly important in characterizing the newer modalities which have many 
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touted benefits in terms of toxicity and adverse effects. Together, these data will be 
important to strengthen future cost-effectiveness analyses and convey a more accurate 
and to date perception of the quality of life benefits of radiation therapy. However, 
collecting utility data can be laborious and challenging. Future work using existing survey 
instruments such as the Short Form (36) Health Survey (SF-36) may be one way to 
address this need because there are validated algorithms that are able to transform SF-
36 data into utilities. 92 Conceivably, using this survey instrument we will be able to 
derive chronological changes in utility during various stages of cancer care for various 
radiation therapy modalities in women of varying ages. Finally, future work incorporating 
future trial-based effectiveness data will be critical to re-assessing cost-effectiveness of 
various radiation therapy modalities.  
 
4.3: CONCLUSIONS 
Proper evaluation of new technologies that considers benefits, risks, and costs in 
specific populations is critical towards promoting appropriate clinical care. As new 
technologies continually emerge into clinical practice, it will be important to 
comprehensively assess factors driving adoption, incentives affecting clinical decision 
making, and ultimately patient outcomes.  Careful and thorough evaluation has 
influential consequences in spuring discussion and shaping policies that have positive 
impact on patient safety, quality, and outcome.  
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Figure 2.1: Percent of women receiving any radiation therapy or brachytherapy based 
on age and hospital ownership. NFP: not-for-profit; FP: for-profit 
 
Figure 3.1: Cost-Effectiveness of EBRT and Newer Modalities based on Patient Age 
and Comorbidity (for example, a patient who is 77 years old with 1 comorbidity has a 10-
year survival that falls between 25-50%.  For EBRT, this estimated 10-year survival 
probability corresponds to a cost-effectiveness ratio between $44,678/QALY and 
$68,547/QALY.) 
 
Figure 3.2: One way sensitivity analysis for EBRT in women aged 70-74 
 
Figure 3.3: Incremental benefit in QALYs for newer modalities to be cost-effective 
 
 
 
Appendix 2.1: Procedure and diagnosis codes used in analysis 
 
Appendix 2.2: Sample selection algorithm 
 
Appendix 3.1: Basic Model Bubble Diagram 
 
Appendix 3.2: HCPCS and ICD-9 codes used in analysis 
 
 
 	  	  	  	  
37 	  
FIGURES 	  
FIGURE 2.1 Percent of women receiving any radiation therapy or brachytherapy based on age 
and hospital ownership 
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FIGURE 3.1: Cost-Effectiveness of EBRT and Newer Modalities based on Patient Age and 
Comorbidity (for example, a patient who is 77 years old with 1 comorbidity has a 10-year 
survival that falls between 25-50%.  For EBRT, this estimated 10-year survival probability 
corresponds to a cost-effectiveness ratio between $44,678/QALY and $68,547/QALY.) 
 
 	  	   	  	  	  	  	  	  	  
 
 
 	  	  
 
 
 
 
 
 
 
 
 
 
 
 
*Conditions used to create comorbidity categories included congestive heart failure, cardiac 
arrhythmias, valvular disease, pulmonary circulation disorders, peripheral vascular disorders, 
paralysis, other neurological disorders, chronic pulmonary disease, diabetes, renal failure, liver 
disease, AIDS/HIV, lymphoma, metastatic cancer, solid tumor without metastasis, rheumatoid 
arthritis/collagen, coagulopathy, weight loss, fluid and electrolyte disorders, deficiency anemia, 
alcohol abuse, drug abuse, psychoses, depression. 
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FIGURE 3.2: One way sensitivity analysis for EBRT in women aged 70-74 
 
 
 
 
 
 
*the incremental utility benefit of RT (versus no RT) in either a recurrence or no recurrence state 
was varied by  ±50%  
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FIGURE 3.3: Incremental benefit in QALYs for newer modalities to be cost-effective 
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TABLES 	  
Table 2.1 Characteristics of patients who received radiation therapy according to ownership of 
the hospital where breast-conserving surgery was performed. 
 
 
 Non-profit  For-profit  
 N %  N % p-value 
Total 22496   2816   
Hospital characteristics       
Hospital volume      <0.001 
   Q1 (1-7) 4170 18.5  855 30.4  
   Q2 (8-14) 4284 19.0  862 30.6  
   Q3 (15-22) 4347 19.3  445 15.8  
   Q4 (23-38) 5013 22.3  338 12.0  
   Q5 (39-142) 4682 20.8  316 11.2  
Patient Characteristics       
Age at breast-conserving surgery      0.53 
66-69 5964 26.5  765 27.2  
70-74 6673 29.7  834 29.6  
75-79 5209 23.2  619 22.0  
80-84 3412 15.2  428 15.2  
85-94 1238 5.5  170 6.0  
Race      <0.001 
White 20542 91.3  2517 89.4  
Black 1375 6.1  183 6.5  
Other 579 2.6  116 4.1  
Year of surgery      0.83 
2008 14610 64.9  1823 64.7  
2009 7886 35.1  993 35.3  
Residence in metro county      0.001 
Yes 18038 80.2  2330 82.7  
No    4458 19.8  486 17.3  
       
Clinical characteristics       
Comorbidity      0.72 
0 conditions 12761 56.7  1584 56.3  
1-2 conditions 7995 35.5  1021 36.3  
≥3 conditions 1740 7.7  211 7.5  
Tumor laterality      0.41 
Right-sided 9715 43.2  1227 43.6  
Left-sided 10056 44.7  1228 43.6  
Unknown 2725 12.1  361 12.8  
Axillary node dissection      0.06 
No 6285 27.9  740 26.3  
Yes 16211 72.1  2076 73.7  
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  Non-profit  For-profit  
 N %  N % p-value 
Chemotherapy      0.04 
No chemotherapy 19721 87.7  2429 86.3  
Chemotherapy started in month prior  
through month after surgery 
920 4.1  115 4.1  
Chemotherapy started in 31-365 days  
after surgery 
1855 8.3  272 9.7  
Hospital admission*      0.96 
No 19460 86.5  2435 86.5  
Yes 3036 13.5  381 13.5  
Screening mammogram*      0.06 
No 5102 22.7  683 24.3  
Yes 17394 77.3  2133 75.8  
Flu shot*      0.02 
No 9390 41.7  1242 44.1  
Yes 13106 58.3  1574 55.9  
Visit to primary care physician*      0.12 
No 686 3.1  71 2.5  
Yes 21810 97.0  2745 97.5  
       
Health system characteristics       
State certificate of need for radiation 
facility 
     
<0.001 
No 11820 52.5  1773 63.0  
Yes 10676 47.5  1043 37.0  
HRR-level two-year mammography 
rate among female Medicare 
enrollees 67-69, in quintiles 
     
<0.001 
   Q1 (50.1-59.7) 3941 17.5  793 28.2  
   Q2 (59.8-62.4) 4400 19.6  706 25.1  
   Q3 (62.4-64.9) 4652 20.7  468 16.6  
   Q4 (65.0-68.4) 4762 21.2  441 15.7  
   Q5 (68.4-76.1) 4741 21.1  408 14.5  
Radiation oncologist density per 
100,000 residents, in quintiles 
     
<0.001 
   Q1 (0.2-1.0) 4397 19.6  688 24.4  
   Q2 (1.0-1.1) 4078 18.1  660 23.4  
   Q3 (1.1-1.2) 4531 20.1  624 22.2  
   Q4 (1.2-1.4) 4818 21.4  293 10.4  
   Q5 (1.4-2.5) 4672 20.8  551 19.6  
 
 
*In year prior to breast-conserving surgery
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Table 2.2 Associations between patient, hospital, and health system characteristics and the receipt of brachytherapy 
  Percent 
Receiving 
Brachytherapy 
Unadjusted Adjusted 
  OR 95% CI P-value OR 95% CI P-value 
Hospital characteristics              
Hospital profit status       0.01     <0.001 
Non-profit 15.2 1.00 -- --  1.00 -- --   
For-profit 20.2 1.28 1.06 1.55  1.50 1.23 1.84   
Hospital volume       <0.001     <0.001 
   Q1 (1-7) 9.1 1.00 -- --  1.00 -- --   
   Q2 (8-14) 13.2 1.40 1.15 1.69  1.38 1.13 1.67   
   Q3 (15-22) 16.6 1.98 1.61 2.43  2.02 1.64 2.50   
   Q4 (23-38) 20.0 2.21 1.79 2.72  2.24 1.80 2.77   
   Q5 (39-142) 19.6 1.93 1.53 2.44  2.00 1.57 2.53   
Patient characteristics             
Age at BCS      0.52       
66-69 16.0 1.00 -- --        
70-74 15.6 0.99 0.89 1.09        
75-79 15.8 0.97 0.86 1.08        
80-84 15.7 0.90 0.80 1.03        
85-94 15.3 0.91 0.76 1.09        
Race      0.02     0.06 
White 15.9 1.00 -- --  1.00 -- --   
Black 13.2 0.77 0.65 0.92  0.81 0.67 0.97   
Other 15.0 0.99 0.77 1.27  1.04 0.80 1.33   
Year of surgery      0.53       
2008 15.7 1.00 -- --        
2009 15.8 0.97 0.90 1.06        
Residence in metro county      0.51       
Yes 16.4 1.00 -- --        
No    12.9 0.96 0.84 1.09        
	  	  
 	  
44 
  Percent 
Receiving 
Brachytherapy 
Unadjusted Adjusted 
  OR 95% CI P-value OR 95% CI P-value 
Clinical characteristics             
Comorbidity      0.59       
0 conditions 15.6 1.00 -- --        
1-2 conditions 16.0 1.03 0.95 1.12        
≥3 conditions 15.4 0.96 0.83 1.12        
Tumor laterality      <0.001     <0.001 
Right sided 15.6 1.00 -- --  1.00 -- --   
Left sided 16.7 1.10 1.02 1.20  1.11 1.02 1.21   
Unknown 12.9 0.81 0.71 0.93  0.83 0.72 0.96   
Axillary node dissection      <0.001     <0.001 
No 11.6 1.00 -- --  1.00 -- --   
Yes 17.3 1.46 1.32 1.60  1.52 1.38 1.68   
Chemotherapy (composite)      <0.001     <0.001 
No chemotherapy 16.3 1.00 -- --  1.00 -- --   
Chemotherapy started in  
month prior through month  
after surgery 
7.2 0.33 0.25 0.43  0.32 0.24 0.41   
Chemotherapy started in 31- 
365 days after surgery 
13.8 0.73 0.63 0.84  0.70 0.61 0.82   
Hospital admission  
(year prior to surgery) 
     0.04       
No 15.9 1.00 -- --        
Yes 14.3 0.89 0.79 1.00        
Screening mammogram  
(year prior to surgery) 
     <0.001     <0.001 
No 13.4 1.00 -- --  1.00 -- --   
Yes 16.4 1.45 1.32 1.60  1.44 1.30 1.59   
Flu shot  
(year prior to surgery) 
     0.34       
No 15.4 1.00 -- --        
Yes 16.0 1.04 0.96 1.13        
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  Percent 
Receiving 
Brachytherapy 
Unadjusted Adjusted 
  OR 95% CI P-value OR 95% CI P-value 
Visit to PCP  
(year prior to surgery) 
     0.03       
No 12.0 1.00 -- --        
Yes 15.8 1.32 1.03 1.71        
 
Health system characteristics 
            
State CON for radiation facility      0.09       
No 17.5 1.00 -- --        
Yes 13.6 0.85 0.71 1.02        
HRR-level two-year 
mammography rate among 
female Medicare enrollees 67-69, 
in quintiles 
     0.04     0.007 
   Q1 (50.1-59.7) 17.1 1.00 -- --  1.00 -- --   
   Q2 (59.8-62.4) 17.2 1.05 0.76 1.44  1.04 0.76 1.44   
   Q3 (62.4-64.9) 16.3 0.92 0.67 1.27  0.89 0.64 1.23   
   Q4 (65.0-68.4) 16.1 0.80 0.58 1.10  0.75 0.55 1.04   
   Q5 (68.4-76.1) 12.0 0.67 0.49 0.92  0.62 0.45 0.85   
Radiation oncologist density per 
100,000 residents, in quintiles 
     0.26       
   Q1 (0.2-1.0)  1.00 -- --        
   Q2 (1.0-1.1)  0.92 0.69 1.23        
   Q3 (1.1-1.2)  0.85 0.63 1.16        
   Q4 (1.2-1.4)  0.84 0.63 1.13        
   Q5 (1.4-2.5)  0.70 0.51 0.96        
 
 
*Adjusted for the following health system characteristics: state certificate of need (CON), HRR level 2-year mammography rate in 
quintiles, and radiation oncologist density per 100,000 enrollees 	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Table 3.1 Model Inputs 
 
* Base case estimate 
 
 
 
 
 	  	  	  	  	  	  	  	  	  	  	  	  	  
Model Assumptions  Ref 
Utilities 
Conservative Surgery and Radiation Therapy with No Recurrence 
Conservative Surgery and Radiation Therapy with Isolated Local Recurrence 
Conservative Surgery Alone with No Radiation Therapy with No Recurrence* 
Conservative Surgery Alone with No Radiation Therapy with Isolated Local Recurrence* 
 
0.92-0.758 
0.82-0.676 
0.88-0.725 
0.81-0.667  
71, 78 
 
Distant Metastases   0.7-0.577  
Survival (All Women)   
5 year survival  
70-74 91.1% 
75-79 86.6% 
80-94 70.3% 
10-year survival  
70-74 73.6% 
75-79  61.2% 
80-94 33.4% 
Annual Recurrence Probability  
No RT* 0.0036 
RT 0.0027 
Annual Metastasis Probability  
1-3 years 0.0064 
4-10 years 0.0096 
Annual Death Probability from Metastatic Breast Cancer  0.210-0.238 74 
Annual Discount Rate 3% 
Cancer Related Costs per patient  
No RT* $5,986 
EBRT $16,294 
IMRT $25,240 
Brachytherapy $24,235 
Other Costs  
Recurrence (Mastectomy) $5,534 
Metastatic Care $35,000 77 
Continued Phase Costs $156-$705 
Death (last year of life) $28,580 
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Table 3.2 Cost and Effectiveness Estimates 
 Age No RT EBRT IMRT Brachytherapy 
Costs ($) 70-74 31,434 41,703 50,649 49,644 
 75-79 40,907 51,177 60,123 59,118 
80-94 71,803 82,078 91,024 90,019 
ΔQALY 70-74 - 0.28 (0.28) (0.28) 
 75-79 - 0.25 (0.25) (0.25) 
80-94 - 0.20 (0.20) (0.20) 
Incremental  
Cost-Effectiveness Ratio 
($/QALY)* 
70-74 - 36,675 68,625 65,036 
75-79 - 41,080 76,864 72,844 
80-94 - 51,375 96,105 91,080 
 All  - 43,015 80,478 76,270 
Number Needed to Treat to 
Prevent One Recurrence 
All - 125   
 
- denotes base case scenario;  
italics indicates model assumption that effectiveness of newer modalities is the same as EBRT 
* Incremental Cost-Effectiveness Ratios for newer modalities (IMRT, brachytherapy) are compared to no RT 
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APPENDICES 
APPENDIX 2.1 Procedure and diagnosis codes used in analysis 
 
 
  HCPCS ICD-9 PROCEDURE ICD-9 DIAGNOSIS 
Breast Surgery 
19110, 19120, 
19125, 19126, 
19160, 19162, 
19301, 19302 
85.20, 85.21, 85.22, 
85.23, 85.25,  
Whole-Breast Irradiation 
77402, 77403, 
77404, 77406, 
77407, 77408, 
77409, 77411, 
77412, 77413, 
77414, 77416, 
77418, 0073T, 
G0174   
Brachytherapy 
77761, 77762, 
77763, 77776, 
77777, 77778, 
77781, 77782, 
77783, 77784, 
77785, 77786, 
77787, 77799, 
0182T   
Tumor laterality 
This was using the 
HCPCS modifier 
codes for left and 
right side, which is 
optionally included 
for procedures     
Axillary node dissection 
19302, 38740, 
38745, 38525, 
38500 40.23, 40.51   
Chemotherapy 
96400-96549, 
Q0083-Q0085, 
J9000-J9999, 
G0355-G0362, 
J8510, J8520, 
J8521, J8530, 
J8560, J8565, 
J8600, J8610, 
J8700 99.25 V58.1 
Screening mammogram 76092, 77057, 
G0202, G0203   
V76.1, V76.11, 
V76.12 
Flu shot 
  
90656, 90658, 90659, 
90660, 90661, 90662, 
90724 V04.81 
Visit to primary care physician 
  
99202, 99203, 99204, 
99205, 99212, 99213, 
99214, 99215, 99387, 
99397   
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APPENDIX 2.2 Sample Selection Algorithm 
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APPENDIX 3.1 
 
 
 
 
 
*Upon experiencing a recurrence, there is a two-year decrease in utility   
pDeath (background): annual probability of death (refers to background mortality) 
pDeath (metastatic cancer): annual probability of death from metastatic breast cancer 
pRecurrence: annual probability of recurrence 
pMetastasis: annual probability of metastasis  
 
 
 
 
 
 
 
 
Metastasis 
No 
Recurrence Recurrence 
	  
Death 
pRecurrence 
pMetastasis pMetastasis 
pDeath  
(metastatic cancer) 
	  
	  	  
	  
pDeath  
(background) 
	  
pDeath  
(background) 
* 
±RT 
Women with 
Early Stage 
Breast Cancer 
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APPENDIX 3.2 
 
 Healthcare Common 
Procedure Coding System 
International Classification 
of Diseases, 9th revision 
 
Treatment   
Breast-conserving surgery 
 
19110, 19120, 19125, 19126, 
19160, 19162, 19301, 19302 
 
85.20, 85.21, 85.22, 85.23, 
85.25, 
 
External beam radiation 
therapy 
 
77402, 77403, 77404, 77406, 
77407, 77408, 77409, 77411, 
77412, 77413, 77414, 77416, 
 
 
Intensity modulated 
radiotherapy 
 
  
77301, 77418, 0073T, G0174 
 
 
  
Brachytherapy 
 
77761, 77762, 77763, 77776, 
77777, 77778, 77781, 77782, 
77783, 77784, 77799, 0182T, 
19296, 19297, 19298, C9714, 
C9715 
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